Monomer for optical component, polymerizable composition for optical component, cured product, spectacle lens, and method for producing monomer for optical component
US-2024336589-A1 · Oct 10, 2024 · US
Selective matrix metalloproteinase inhibitors
US9604957B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9604957-B2 |
| Application number | US-201515120508-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 20, 2015 |
| Priority date | Feb 20, 2014 |
| Publication date | Mar 28, 2017 |
| Grant date | Mar 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of Formula I: wherein R 1 is —CH 2 —NHR a wherein R a is H or (C 1 -C 6 )alkanoyl; —NH—C(═NH)—NH 2 ; or J is S or O; G, T, and Q are each independently H, (C 1 -C 6 )alkyl, or —CN; each R 2 is independently…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9604957B2 cover?
- The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological d…
- Who is the assignee on this patent?
- Univ Notre Dame Du Lac
- What technology area does this patent fall under?
- Primary CPC classification C07D331/02. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).